Sichuan Kelun-Biotech Biopharmaceutical recently faced a 14.8% decline following its presentations at the 2026 ASCO Annual Meeting, where it showcased promising data on its oncology pipeline, particularly for non-small cell lung cancer (NSCLC).
The company highlighted findings from its Phase III and Phase II trials, notably the combination of sacituzumab tirumotecan and pembrolizumab, which demonstrated improved progression-free survival compared to pembrolizumab alone. Additionally, lunbotinib fumarate showed significant response rates in RET fusion-positive NSCLC, and the first-in-human results for its B7-H3 ADC SKB500 were encouraging. These developments indicate Kelun-Biotech's shift from an early-stage focus to a more robust oncology portfolio.
Investors are now reevaluating the potential of Kelun-Biotech based on these ASCO results, particularly the regulatory prospects linked to the New Drug Application for lunbotinib in China. The company’s future revenue projections require substantial growth, with expectations of CN¥6.9 billion in revenue and CN¥1.6 billion in earnings by 2029. However, the reliance on successful regulatory approvals and the risks of underperformance in late-stage programs present challenges for investors.
As Kelun-Biotech navigates these pivotal moments, its ability to convert clinical successes into commercial viability will be critical. The recent data could serve as a turning point, but potential setbacks in regulatory pathways could significantly impact its investment narrative. The broad range of fair value estimates from analysts suggests a divided outlook, emphasizing the importance of careful consideration for potential investors.